Severe and prolonged hypoglycemia triggered by long-acting octreotide in a patient with malignant mesenchymal tumor: Case report

Journal of Chemotherapy

Volumn 15, Issue 1, 2003, Pages 85-88

  Sari, Ramazan ^a   Altunbas, H ^a   Ozdogan, M ^a   Gurer, E I ^a   Karayalcin, U ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Hypoglycemia; Malignancy; Octreotide; Somatostatin analogues

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; PREDNISOLONE; RECOMBINANT GLUCAGON; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOSTATIN DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONFUSION; DISEASE COURSE; DISEASE SEVERITY; DRUG POTENCY; EMERGENCY WARD; FEMALE; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPOGLYCEMIA; MESENCHYMOMA; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; TREMOR;

EID: 0037301054     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.1.85     Document Type: Article

References (15)

1. Immerman SC, Sener SF, Khandekar JD. Causes and evaluation of tumor-induced hypoglycemia. Arch Surg 1982;117 (7): 905-8.
2. Gorden P, Comi RJ, Maton PN, Go VL. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 35-50.
3. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995; 80 (11): 3267-72.
4. Priou A, Levesque G, Simonetta C, Lancranjan I, Roger P, Jaquet P. Long acting sandostatin (sandostatin LAR) in the treatment of acromegaly. Ann Endocrinol (Paris) 1995; 56 (3): 213-8.
5. Lunetta M, De Mauro M, Le Moli R, Nicoletti F. Effects of octreotide on glycaemic control disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients. Diabetes Res Clin Pract 1997; 38: 81-89.
6. Brunner JE, Kruger DF, Basha MA, Meiri E, Kaatz SS. Hypoglycemia in acromegalic patients treated with long acting somatostatin analogue (SMS 201-995). Horm Metab Res 1989; 21 (5): 282-284.
7. Gama R, Marks V, Wright J, Teale JD. Octreotide exacerbated fasting hypoglycemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Clin Endocrinol (Oxf) 1995; 43 (1): 117-120.
8. Krejs G. Physiological role of somatostatin in the digestive tract: gastric acid secretion, intestinal absorption, and motility. Scand J Gastroenterol Suppl 1986; 119: 47-53.
9. th edition. WB. Saunders Company, Philadelphia, 2001, Volume 1: 929-930.
10. st edition. W.B. Saunders Company, Philadelphia, 2000:1050.
11. Ron D, Powers AC, Pandian MR, Godine JE, Axelrod L. Increased insulin-like growth factor II production and cosequent seppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. J Clin Endocrinol Metab 1989; 68: 701-6.
12. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless R. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31 (11): 1133-40.
13. Lamberts S, Uitterlinden G, Verschoor P, van Dongen L, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985; 313 (25):1576-80.
14. Daughaday WH. Hypoglycemia in patients with nonislet cell tumors. Endocrinol Metab Clin North Am 1989;18 (1): 91-101.
15. Baxter RC, Holman SR, Corbould A, Stranks S, Ho PJ, Braund W. Regulation of the insulin-like growth factors and their binding proteins by glucocorticoid and growth hormone in nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 1995; 80 (9): 2700-8.